Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep-vein thrombosis. Results from the OTIS-DVT registry by Spirk, D et al.
Thrombosis and Haemostasis 105.1/2011
1 © Schattauer 2011Blood Coagulation, Fibrinolysis and Cellular Haemostasis 
Inconsistencies in the planning of the duration of anticoagulation 
among outpatients with acute deep-vein thrombosis 
Results from the OTIS-DVT Registry 
David Spirk1*; Marc Husmann2*; Torsten Willenberg3; Martin Banyai4; Ulrich Frank5; Thomas Baldi6; Beatrice Amann-Vesti2;  
Iris Baumgartner3; Nils Kucher3 
1Medical Department, sanofi-aventis (suisse) sa, Meyrin, Switzerland; 2Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland; 3Division of Vascular Medicine, Swiss 
Cardiovascular Center, University Hospital Bern, Bern, Switzerland; 4Department of Internal Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland; 5Department of Internal 
Medicine, Cantonal Hospital Chur, Chur, Switzerland; 6Department of Internal Medicine, University Hospital Basel, Basel, Switzerland 
Summary 
Three-month anticoagulation is recommended to treat provoked or first 
distal deep-vein thrombosis (DVT), and indefinite-duration anticoagu-
lation should be considered for patients with unprovoked proximal, un-
provoked recurrent, or cancer-associated DVT. In the prospective Out-
patient Treatment of Deep Vein Thrombosis in Switzerland (OTIS-DVT) 
Registry of 502 patients with acute objectively confirmed lower extrem-
ity DVT (59% provoked or first distal DVT; 41% unprovoked proximal, 
unprovoked recurrent, or cancer-associated DVT) from 53 private prac-
tices and 11 hospitals, we investigated the planned duration of anti-
coagulation at the time of treatment initiation. The decision to admin-
ister limited-duration anticoagulation therapy was made in 343 (68%) 
patients with a median duration of 107 (interquartile range 91–182) 
days for provoked or first distal DVT, and 182 (interquartile range 
111–184) days for unprovoked proximal, unprovoked recurrent, or 
Correspondence to: 
Nils Kucher, MD 
Division of Vascular Medicine 
Swiss Cardiovascular Center 
University Hospital Bern 
3010 Bern, Switzerland 
Tel.: +41 31 632 7963, Fax: +41 31 632 4380 
E-mail: nils.kucher@insel.ch 
cancer-associated DVT. Among patients with provoked or first distal 
DVT, anticoagulation was recommended for <3 months in 11%, =3 
months in 63%, and for an indefinite period in 26%. Among patients 
with unprovoked proximal, unprovoked recurrent, or cancer-associated 
DVT, anticoagulation was recommended for <6 months in 22%, 6–12 
months in 38%, and for an indefinite period in 40%. Overall, there was 
more frequent planning of indefinite-duration therapy from hospital 
physicians as compared with private practice physicians (39% vs. 28%; 
p=0.019). Considerable inconsistency in planning the duration of anti-
coagulation therapy mandates an improvement in risk stratification of 
outpatients with acute DVT.  
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Introduction 
The annual incidence of acute symptomatic deep-vein thrombosis 
(DVT) varies between 220,000–400,000 in the United States and 
exceeds 460,000 in six large European Union countries (1–4). After 
discontinuation of anticoagulation therapy, the risk of recurrence 
within 12 months ranges between 5% and 10% in patients with ve-
nous thromboembolism (VTE) provoked by a transient risk factor, 
including surgery, hospitalisation, immobilisation, oestrogen ther-
apy, pregnancy, or prolonged travel (5–7). However, in patients 
with unprovoked or idiopathic VTE, the risk of recurrence is sub-
stantially higher and ranges between 15% and 30% (7–10). In ad-
dition, thrombosis localisation (distal or proximal) and episode 
(first or subsequent) modify the risk of recurrence (9–13). In pa-
tients with provoked VTE, three-month anticoagulation therapy 
halves the risk of recurrence within the next year in comparison to 
shorter treatment periods (5, 9, 10). In comparison to placebo, in-
definite-duration therapy with conventional-intensity vitamin K 
antagonists (international normalised ratio [INR] target 2.5, range 
2.0–3.0) reduces the risk of thrombosis recurrence by up to 90% in 
patients with unprovoked VTE (11, 14). According to current con-
sensus guidelines of the American College of Chest Physicians 
(ACCP), patients with provoked or first distal DVT should receive 
anticoagulation treatment for three months, and in patients with 
unprovoked proximal, unprovoked recurrent, or cancer-associ-
ated DVT indefinite-duration anticoagulation therapy should be 
considered (15). For each individual patient, the benefits of indefi-
nite-duration anticoagulation therapy should be balanced against 
the risk of bleeding and its indication reassessed on a regular basis 
(16). The 2008 ACCP recommendations for the duration of anti-
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coagulation were accepted by the Swiss Expert Group (17). In the 
prospective Outpatient Treatment of Deep Vein Thrombosis in 
Switzerland (OTIS-DVT) Registry, we investigated the planned 
duration of anticoagulation therapy in DVT outpatients at the 
time of treatment initiation.  
Methods 
Patients 
Overall, 502 consecutive patients ≥18 years of age who were treated 
for acute objectively confirmed lower extremity DVT with or with-
out pulmonary embolism (PE) on an outpatient basis and receiv-
ed antithrombotic therapy for at least five days were enrolled in the 
prospective OTIS-DVT Registry. Emergency department phys-
icians and vascular medicine physicians from eleven Swiss hospi-
tals as well as vascular medicine physicians, internal medicine 
physicians or general practitioners from 53 private practices par-
ticipated in the study and recruited patients during outpatient vi-
sits between March 1, 2009 and March 31, 2010. The exclusion 
criteria were acute PE without DVT, untreated clinically suspected 
acute DVT, and DVT with subsequent hospitalisation. Accepted 
tests to objectively confirm DVT included compression ultra-
sound and conventional phlebography, and PE imaging tests in-
cluded contrast-enhanced chest computed tomography, venti-
lation perfusion scan, or conventional pulmonary angiography. 
OTIS-DVT did not issue any recommendations for the diagnosis 
and treatment of DVT. The study was approved by the ethics com-
mittees in all participating cantons according to local regulations 
in Switzerland. 
Data, definitions and statistical analysis 
Anonymous data were prospectively collected using a standardised 
case report form (CRF): specifically, information on patient age, sex, 
weight, height, localisation and episode of DVT, confirmatory test of 
VTE diagnosis, risk factors for VTE, such as surgery within 30 days, 
immobilisation defined as <30 minutes (min) walk per day for more 
than three days, active cancer, acute medical illnesses, contraceptive 
or substitutive hormonal therapy, pregnancy, recent prolonged 
travel, and the planned duration of pharmacological treatment. 
Thrombosis categorisation as provoked or unprovoked was based 
on the assessment of VTE risk factors according to the ACCP guide-
lines criteria (15); the CRF itself did not mandate categorisation of 
thrombosis as provoked or unprovoked. Physicians were asked to 
provide the initiation and termination dates indicating the planned 
duration of anticoagulation. No termination date had to be provided 
in case of planned indefinite-duration anticoagulation therapy. Data 
were entered solely by the treating physician.  
Patients were divided into two groups according to the duration 
of anticoagulation selected by the physician: the first group consisted 
of patients with limited-duration anticoagulation defined as the 
presence of an exact date range for the duration of anticoagulation 
treatment; the second group consisted of patients with planned in-
definite-duration anticoagulation therapy defined as long-term 
treatment without a planned termination date. According to the 
ACCP consensus guidelines (15), we also grouped the patients into 
those with an indication for three-month anticoagulation therapy, 
comprising provoked or first distal DVT, and patients with an indi-
cation for indefinite-duration anticoagulation therapy, comprising 
those with unprovoked proximal, unprovoked recurrent, or cancer-
associated DVT. Provoked DVT was defined as DVT associated with 
surgery, hospitalisation, immobilisation for more than three days, 
oestrogen therapy, pregnancy, or prolonged (>5 hours h) travel, all 
within 30 days prior to VTE diagnosis (15). For cancer-associated 
DVT, the ACCP guidelines recommend anticoagulation indefinitely 
or until the cancer is resolved (15). Since cancer cure is unpredict-
able, we considered indefinite-duration anticoagulation to be the 
most suitable initial recommendation for cancer-associated DVT. 
Patients with combined proximal and distal DVT were analysed in 
the proximal DVT group. 
Discrete variables are presented as frequencies and percentages, 
and group comparisons were performed using the chi-square or 
Fisher’s exact test. Continuous variables with a normal distribu-
tion are described as means with standard deviations, and group 
comparisons were performed with the t-test; continuous variables 
with skewed distribution are presented as medians with interquar-
tile ranges (IQR), and group comparisons were performed using 
the Wilcoxon ranksum test. All reported p-values are two tailed. 
Data were analysed using STATA 10 software (STATACorp LP, Col-
lege Station, TX, USA). Data collection and database entry was per-
formed by an independent data coordinating center (la volta stat-
istics, Zurich, Switzerland).  
Results 
Patient characteristics 
Among the 502 enrolled patients, the mean age was 58 ± 17 years, 
55% were women, the mean weight was 78.3 ± 15.9 kg, and the mean 
body mass index (BMI) 27.2 ± 5.1 kg/m2 (Table 1). Overall, 168 
(33%) patients were enrolled from hospital physicians in an emerg-
ency department, and 334 (67%) from private practice physicians; 
140 (28%) were hospitalised within 30 days prior to enrolment, 103 
(21%) were obese with BMI >30 kg/m2, 94 (19%) immobile for >3 
days, 62 (12%) had surgery within 30 days, and 53 (11%) active 
cancer. One per cent patients had a creatinin-clearance of less than 
30 ml/min, 1% active bleeding, and none had heparin-allergy or he-
parin induced thrombocytopenia prior to enrolment. 
In total, 294 (59%) patients had provoked or first distal DVT, 
and 208 (41%) unprovoked proximal, unprovoked recurrent, or 
cancer-associated DVT. Proximal DVT was diagnosed in 227 
(45%) patients, isolated distal DVT in 218 (44%), and DVT with 
concomitant symptomatic PE in 57 (11%). In total, 379 (75%) pa-
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tients had the first episode of acute DVT, 78 (16%) had ipsilateral 
and 45 (9%) contralateral DVT recurrence. DVT was unprovoked 
in 250 (50%) patients.  
Planned duration of anticoagulation 
The decision to administer limited-duration anticoagulation ther-
apy was made in 343 (68%) patients with a median duration of 107 
(IQR 91–182; mean ± SD 139 ± 71) days for provoked or first dis-
tal DVT, and 182 (IQR 111–184; mean ± SD 197 ± 128) days for un-
provoked proximal, unprovoked recurrent, or cancer-associated 
DVT (Fig. 1). In comparison to patients with limited-duration 
anticoagulation therapy, the 159 (32%) patients with planned in-
definite-duration anticoagulation therapy more frequently had 
unprovoked DVT (62% vs. 44%, p <0.001), active cancer (21% vs. 
6%, p<0.001), were leaner (76 vs. 80 kg, p=0.017), and were less 
often hospitalised within 30 days prior to enrolment (19% vs. 32%, 
p=0.002), had surgery within 30 days (6% vs. 15%, p=0.005), or 
immobilisation for more than three days (13% vs. 21%, p=0.031). 
A high proportion of patients with first distal DVT received a pre-
scription for extended anticoagulation therapy beyond three 
months or for an indefinite period (Table 2). 
Among patients with provoked or first distal DVT, anticoagu-
lation was recommended for <3 months in 11%, ≥3 months in 
Table 1: Patient characteristics according to 
the planned duration of anticoagulation 
treatment.  
 Total 
N = 502 
Limited- 
duration anti-
coagulation 
therapy 
N = 343 
Indefinite- 
duration anti-
coagulation  
therapy 
N = 159 
P-value 
Age, years ± SD 57.8 ± 17.0 57.9 ± 16.4 57.7 ± 18.1 0.90 
Women, n (%) 273 (55.2) 185 (54.7) 88 (56.1) 0.78 
Weight, kg ± SD 78.3 ± 15.9 79.5 ± 15.9 75.6 ± 15.7 0.017 
BMI, kg/m2 ± SD 27.2 ± 5.1 27.5 ± 5.0 26.5 ± 5.4 0.07 
Proximal DVT, n (%) 227 (45.2) 158 (46.1) 69 (43.4) 0.58 
Isolated distal DVT, n (%) 218 (43.4) 140 (40.8) 78 (49.1) 0.08 
DVT with concomitant PE, n (%) 57 (11.4) 45 (13.1) 12 (7.5) 0.07 
Recurrent DVT, n (%) 123 (24.5) 76 (22.2) 47 (29.6) 0.07 
Surgery within 30 days, n (%) 62 (12.4) 52 (15.2) 10 (6.3) 0.005 
Active cancer, n (%) 53 (10.6) 20 (5.8) 33 (20.8) <0.001 
BMI, body mass index; DVT, deep-vein thrombosis; n, number; PE, pulmonary embolism; SD, standard devi-
ation. 
Provoked DVT, n (%) 252 (50.2) 192 (56.0) 60 (37.8) <0.001 
Unprovoked first distal DVT, n (%) 70 (14.0) 38 (11.1) 32 (20.1) 0.006 
Unprovoked first proximal DVT, n (%) 93 (18.5) 65 (18.9) 28 (17.6) 0.72 
Unprovoked recurrent DVT, n (%) 87 (17.3) 48 (14.0) 39 (24.5) 0.004 
Prior hospitalisation within 30 days, n (%) 140 (27.9) 110 (32.1) 30 (18.9) 0.002 
Obesity, n (%) 103 (20.5) 76 (22.2) 27 (17.0) 0.18 
Bed rest >3 days within 30 days, n (%) 94 (18.7) 73 (21.3) 21 (13.2) 0.031 
Figure 1: Planned duration of anticoagu-
lation treatment in patients with limited-
duration anticoagulation. The box plots dis-
play the median and interquartile range (IQR, 
the 25th-75th percentiles), and the whiskers dis-
play the upper and lower values within 1.5 
times the IQR beyond the 25th-75th percentile. 
DVT, deep-vein thrombosis. 
63%, and for an indefinite period in 26% (Table 3). Among pa-
tients with unprovoked proximal, unprovoked recurrent, or 
cancer-associated DVT, anticoagulation was recommended for <6 
months in 22%, 6–12 months in 38%, and for an indefinite period 
in 40%. Overall, there was a trend towards more frequent plan for 
the indefinite-duration therapy from hospital physicians as com-
pared with private practice physicians (39% vs. 28%; p=0.019). 
Discussion 
The present analysis from the prospective OTIS-DVT Registry 
showed a large variation in the planned duration of anticoagu-
lation treatment suggesting that there was considerable inconsist-
ency with current consensus guidelines. In total, 63% of the pa-
tients with provoked or first distal DVT received a prescription of 
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Table 2: Planned duration of anticoagu-
lation treatment of provoked and unpro-
voked DVT. 
Table 3: Planned duration of anticoagu-
lation treatment in hospitals and private 
practices.
Event Total Provoked Unprovoked P-value 
All DVT, n (%) 502 (100.0) 252 (50.2) 250 (49.8)  
<3 months (90 days) 38 (7.6) 26 (10.3) 12 (4.8) 0.027 
≥3 to <6 months (90–180 days) 142 (28.3) 82 (32.6) 60 (24.0) 0.038 
≥6 months (>180 days) 163 (32.5) 84 (33.3) 79 (31.6) 0.70 
Indefinite 159 (31.6) 60 (23.8) 99 (39.6) <0.001 
First distal DVT, n (%) 176 (100.0) 106 (60.2) 70 (39.8)  
<3 months (90 days) 27 (15.3) 19 (17.9) 8 (11.4) 0.29 
≥3 to <6 months (90–180 days) 72 (40.9) 49 (46.2) 23 (32.9) 0.09 
≥6 months (>180 days) 16 (9.1) 9 (8.5) 7 (10.0) 0.79 
Indefinite 61 (34.7) 29 (27.4) 32 (45.7) 0.015 
DVT, deep-vein thrombosis. 
First proximal DVT, n (%) 203 (100.0) 110 (54.2) 93 (45.8)  
<3 months (90 days) 6 (3.0) 5 (4.6) 1 (1.1) 0.22 
≥3 to <6 months (90–180 days) 44 (21.7) 27 (24.5) 17 (18.3) 0.31 
≥6 months (>180 days) 102 (50.2) 55 (50.0) 47 (50.5) 1.00 
Indefinite 51 (25.1) 23 (20.9) 28 (30.1) 0.15 
Recurrent DVT, n (%) 123 (100.0) 36 (29.3) 87 (70.7)  
<3 months (90 days) 5 (4.1) 2 (5.6) 3 (3.5) 0.63 
≥3 to <6 months (90–180 days) 26 (21.1) 6 (16.7) 20 (23.0) 0.48 
≥6 months (>180 days) 45 (36.6) 20 (55.5) 25 (28.7) 0.007 
Indefinite 47 (38.2) 8 (22.2) 39 (44.8) 0.025 
Event Total 
N = 502 
Hospital 
N = 168 
Private prac-
tice 
N = 334 
P-value 
Provoked or first distal DVT, n (%) 294 (100.0) 91 (31.0) 203 (69.0)  
<3 months (90 days) 32 (10.9) 10 (11.0) 22 (10.8) 1.00 
≥3 to <6 months (90–180 days) 102 (34.7) 30 (33.0) 72 (35.5) 0.69 
≥6 months (>180 days) 85 (28.9) 23 (25.3) 62 (30.5) 0.41 
Indefinite 75 (25.5) 28 (30.7) 47 (23.2) 0.19 
Unprovoked proximal,  
unprovoked recurrent, or cancer- 
associated DVT, n (%) 
208 (100.0) 77 (37.0) 131 (63.0)  
<3 months (90 days) 6 (2.9) 2 (2.6) 4 (3.0) 1.00 
≥3 to <6 months (90–180 days) 40 (19.2) 12 (15.6) 28 (21.4) 0.36 
≥6 months (>180 days) 78 (37.5) 26 (33.8) 52 (39.7) 0.46 
Indefinite 84 (40.4) 37 (48.0) 47 (35.9) 0.11 
DVT, deep-vein thrombosis; n, number. 
anticoagulants for three or more months. Although the ACCP 
2008 guidelines (15) do not recommend prolonged anticoagu-
lation beyond three months in patients with provoked proximal 
DVT, it may be justified in patients with extensive iliofemoral DVT. 
However, the finding that one third of the patients with first distal 
DVT were assigned to the indefinite-duration anticoagulation 
therapy is concerning. In contrast, we found that only 40% of pa-
tients with unprovoked proximal, unprovoked recurrent, or 
cancer-associated DVT were considered for an indefinite-duration 
anticoagulation therapy. Overall, these findings suggest that the 
decision on planning the duration of anticoagulation was often ar-
bitrary rather than guideline-based.  
There were few differences in clinical characteristics between 
patients with the limited-duration and the indefinite-duration 
anticoagulation therapy, including a higher rate of provoked DVT 
and less frequent active cancer in patients with limited-duration 
anticoagulation therapy. We believe that 1) patient, 2) physician, 
and 3) guideline factors contributed to the observed gap be-
tween our findings and current recommendations. Patient factors 
that likely affected the decision on the duration of anticoagulation 
treatment include the presence of medical co-morbidities, a his-
tory of bleeding complications or an increased risk of bleeding, pa-
tient preferences, and prior difficulties with anticoagulation moni-
toring. Because OTIS-DVT was a prospective study recruiting pa-
tients entirely managed on an outpatient basis, it is less likely that 
patient factors were the main reason for the observed gap between 
guidelines and clinical practice. Physician factors are difficult to as-
sess but likely had major impact on our findings: physician prefer-
ences, unawareness of the importance of whether the DVT was 
provoked or unprovoked, and unawareness of specific recommen-
dations from the current ACCP consensus guidelines (15) and the 
Swiss Expert Group (17). Finally, current guidelines may have con-
tributed to some extent because they do not specifically comment 
on the duration of anticoagulation in certain subsets of patients, 
including provoked extensive iliofemoral DVT, provoked recur-
rent DVT, or first distal DVT in cancer patients. 
In our study, the patient characteristics were similar to those 
previously reported in other observational studies: Proximal DVT 
was diagnosed in 45% of patients in the present study, 42% in the 
Optimisation de l’interrogatoire dans l’évaluation du risque 
thrombo-embolique veineux (OPTIMEV) study (18) and 48% in a 
study by Prandoni et al. (7). Recurrent DVT was present in 25% of 
patients in the current study and 18% in the Swiss Venous Throm-
boembolism Registry (SWIVTER) (19). The proportion of pa-
tients with provoked DVT was slightly higher in OTIS-DVT (50%) 
than in previous clinical trials (35–40%) evaluating different strat-
egies on the duration of anticoagulation therapy (9–11). In com-
parison to hospitalised VTE patients from the SWIVTER registry 
(19), the OTIS-DVT patients appeared to be younger (58 vs. 62 
years) and less often had co-morbidities. However, similar rates of 
active cancer (15%) and concomitant PE (16%) were found 
among patients with the first episode of symptomatic DVT (7). 
Clinical practice data reporting the duration of anticoagulation in 
DVT patients is rather scarce. Among inpatients enrolled in the 
Registro Informatizado de la Enfermedad TromboEmbolica veno-
sa (RIETE) registry (20), 89% of patients with distal DVT and 92% 
with proximal DVT received anticoagulation treatment for at least 
three months. In a prospective cohort study of 1,600 patients with 
the first VTE episode without cancer, 17% were treated with oral 
anticoagulation for at least six months, and <5% were treated for 
more than a year (21). 
The strength of the present study is the prospective multicentre 
enrolment of consecutive patients with acute DVT treated on an 
outpatient basis and the collection of detailed information on VTE 
diagnosis, VTE risk factors, and duration of pharmacological ther-
apy. This is the first national survey providing data on the consist-
ency with recommendations from the ACCP 2008 consensus 
guidelines (15) regarding the planned duration of anticoagulation 
in DVT patients. A weakness of the study is that no detailed data on 
risk factors for bleeding were recorded. Because our population 
consisted of outpatients only, it is unlikely that baseline co-mor-
bidities or bleeding risk factors were the main reasons for with-
holding the indefinite-duration therapy in patients with unpro-
voked proximal, unprovoked recurrent, or cancer-associated DVT. 
In addition, the proportion of patients with active bleeding, hepa-
rin-allergy, heparin-induced thrombocytopenia or severe renal 
failure was very low (1%). Another study limitation is that no ad-
ditional follow-up information on compliance, actual duration 
and outcome of the anticoagulation treatment was collected. It is 
likely that the initial plan on the treatment duration has changed in 
some patients; possible reasons may include difficulties in INR 
monitoring or bleeding complications during anticoagulation 
treatment, cure of a cancer, diagnosis of cancer after DVT diag-
nosis, significant symptomatic post-thrombotic syndrome, or pa-
tient preference. Finally, our data may not necessarily be extrapo-
lated to other countries. 
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What is known about this topic? 
● In patients with provoked venous thromboembolism (VTE), three-
month anticoagulation therapy halves the risk of recurrence with-
in the next year in comparison to shorter treatment periods, and in 
patients with unprovoked VTE, indefinite-duration therapy with 
conventional-intensity vitamin K antagonists reduces the risk of 
thrombosis recurrence by up to 90%. 
● Current consensus guidelines recommend three-month anticoagu-
lation to treat provoked or first distal deep-vein thrombosis (DVT), 
and indefinite-duration anticoagulation should be considered for 
patients with unprovoked proximal, unprovoked recurrent, or 
cancer-associated DVT. 
What does this paper add? 
● Physician recommendations for planning the duration of anti-
coagulation therapy in outpatients with acute DVT are often incon-
sistent and contrast with current consensus guidelines. 
● One third of the patients with first distal DVT and only 40% of pa-
tients with unprovoked proximal, unprovoked recurrent, or cancer-
associated DVT were considered for an indefinite-duration anti-
coagulation therapy. 
In conclusion, there is a need to improve risk stratification in 
outpatients with acute DVT and optimise the duration of anti-
coagulation treatment in both patients with provoked and unpro-
voked DVT. Implementation efforts should include continuing 
medical education, local and practice-specific guidelines for hos-
pital and private practice physicians, and risk assessment models. 
Additionally, future research is necessary to investigate the reasons 
for the observed large variation in the planned duration of treat-
ment, including a systematic questioning the physicians as to the 
reasons for their choices. 
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